Pellvara started as a consulting search. After thirty years in pharmaceutical dermatology — Galderma, Novartis, UCB, Novan, and a start at Johnson & Johnson — Brian Johnson was mapping his next project in professional skincare promotion when he read a paper about what GLP-1 therapy was doing to skin at the cellular level. Being a patient, he knew the visible changes. What he hadn't understood was that skin cells carry GLP-1 receptors and that the medication directly impairs the signaling responsible for collagen, elastin, and moisture retention. The therapy itself was affecting skin structure — not just weight loss pulling things loose.
The topical side was solvable. But you can only consistently apply a cream to the face and a few reachable zones. That coverage gap led to a skin, hair, and nails supplement — designed from the start with a controlled biotin dose after an FDA warning he'd encountered at a dermatology meeting. Then a cohort study of 461,382 GLP-1 patients showed that 22% developed nutritional deficiencies within a year: iron, vitamin D, calcium, protein. If patients were already going to take a supplement for their skin, it made sense to address as many of their real needs as possible.
That's how Pellvara became a system — topicals for where you can reach, a supplement for the whole surface you can't. Nobody else had built it. Fourteen million patients. He funded it himself and started building.
Martina M. Cartwright, PhD, RD
Registered dietitian with a PhD in Nutritional Science and Biomolecular Chemistry (University of Wisconsin-Madison). Thirty years across clinical practice, medical education, and pharmaceutical development — including FDA approval and launch of seven novel drugs. More than fifty peer-reviewed publications. Adjunct faculty, University of Arizona College of Nutrition and Wellness. The only dietitian invited to present at the American Academy of Dermatology annual conference, where her 2024 CME presentation on essential nutrients for skin health shaped the Pellvara Nourish formulation architecture. Prior to the pharmaceutical industry, she was the first dietitian hired by Cirque du Soleil. President of Beacon Science Inc., an independent biomedical consulting firm.
How we create our content
Getting this right matters more to us than getting it out fast. Here's how it actually happens.
We start with the published research — peer-reviewed studies on GLP-1 therapy, dermatology, and nutrition science, the same literature we cite throughout this site. Research and early drafting are done with the help of AI tools, which let us cover this topic in the depth it deserves without a multi-year runway. Every claim is then checked, edited, and either approved or rejected by our own named experts before anything goes live:
Nothing publishes on the basis of a citation existing somewhere — it publishes because a credentialed person looked at the underlying study and the claim we're making from it, and signed off that the two match. If we can't support a claim to that standard, we soften it or leave it out, and you'll see that discipline reflected in how we write: "supports" and "helps maintain," not "cures" or "restores."
We're not going to pretend a person typed every word of every article by hand — that's not how anyone builds a resource like this anymore, and we'd rather be straightforward about it than have you wonder. What we will stand behind, always, is that a real person with real credentials is accountable for what's on this page. If you ever think we've gotten something wrong, tell us — every article links to our References page, and we'd genuinely like to hear about it.